Condition: Breast Cancer · Ovarian Cancer · Endometrial Cancer · Sponsor: Regor Pharmaceuticals Inc.
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
This description comes directly from the study's public registry record.
Sarah Wheeler · 857-331-3898 · Sarah.Wheeler@regor.com
Regor Pharmaceuticals Central Office · 617-315-9070 · RGT-490-101@regor.com
Always discuss trial participation with your own doctor first.
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Houston | Houston, Texas, United States | Recruiting |
| NEXT San Antonio | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07524322